What is the clinical evidence from this study?

Population: Ischemia reperfusion injury. Intervention: Sarpogrelate vs. Untreated ischemia-reperfusion. Primary outcome: Changes in left ventricular developed pressure, left ventricular end diastolic pressure, rate of pressure development, and rate of pressure decay (p=<0.05).

What does this research mean for the field?

Sarpogrelate attenuates ischemia-reperfusion-induced cardiac dysfunction, ultrastructural damage, and depletion of high-energy phosphate stores in isolated rat hearts. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

September 1, 2001Canadian Journal of Physiology and Pharmacology

Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart

Q: What are the key findings of this study?

Sarpogrelate attenuated ischemia-reperfusion-induced changes in cardiac function, ultrastructural damage, and high energy phosphate levels in isolated rat hearts (P < 0.05).

Q: What does this research mean for the field?

Sarpogrelate attenuates ischemia-reperfusion-induced cardiac dysfunction, ultrastructural damage, and depletion of high-energy phosphate stores in isolated rat hearts. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Sarpogrelate attenuates ischemia-reperfusion injury and preserves cardiac function in isolated rat hearts.

P<0.05

Why the study?

The role of serotonin in mediating changes in cardiac function due to ischemia reperfusion is poorly understood.

Does sarpogrelate prevent cardiac injury due to ischemia reperfusion in isolated rat hearts?

Population

Isolated rat hearts subjected to 30 min global ischemia followed by 1 h reperfusion

Comparison

Sarpogrelate infusion vs no treatment during ischemia reperfusion

Design

Preclinical experimental study

Follow-up

1 hour reperfusion

Authors

RTRana M. TemsahUniversity of Ottawa HKHideo KumamotoJikei University School of Medicine NDNaranjan S. DhallaElectrophysiology

Discussion

Member takes

Implication

Sarpogrelate attenuated IR injury in isolated rat hearts; leaves open whether 5-HT2A blockade confers clinical cardioprotection.

Structured PICO

Does sarpogrelate prevent cardiac injury due to ischemia reperfusion in isolated rat hearts?

Population

Isolated rat hearts subjected to global ischemia and reperfusion to evaluate the effects of sarpogrelate.

Intervention

Sarpogrelate (50 nM-0.9 microM) infused 10 min before ischemia as well as during the reperfusion period

Comparator

Untreated isolated rat hearts subjected to ischemia reperfusion (implied)

Outcome

Changes in left ventricular developed pressure, left ventricular end diastolic pressure, rate of pressure development, and rate of pressure decaysurrogate

Main Result

p-value: p=<0.05

Sarpogrelate attenuates ischemia-reperfusion-induced cardiac injury in isolated rat hearts, highlighting the role of serotonin in IR injury.

Cite This Study

Temsah et al. (2001) studied Ischemia reperfusion injury. Sarpogrelate vs. Untreated ischemia-reperfusion was evaluated on Changes in left ventricular developed pressure, left ventricular end diastolic pressure, rate of pressure development, and rate of pressure decay (p=<0.05). Sarpogrelate attenuated ischemia-reperfusion-induced changes in cardiac function, ultrastructural damage, and high energy phosphate levels in isolated rat hearts (P < 0.05).

synapsesocial.com/papers/6ab35f4877cca36e202bc85d https://doi.org/10.1139/y01-047

View Full Paper

Ask AI

Bookmark

Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart

Discussion

Member takes

Implication

Structured PICO

Main Result

Cite This Study

Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart

Discussion

Member takes

Implication

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider